<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712423</url>
  </required_header>
  <id_info>
    <org_study_id>2017-003664-12</org_study_id>
    <nct_id>NCT03712423</nct_id>
  </id_info>
  <brief_title>PET Study With [89Zr]-Df-CriPec® Docetaxel</brief_title>
  <official_title>A Clinical Phase I, Open-label, PET Study With [89Zr]-Df-CriPec® Docetaxel in Patients With Solid Tumours to Assess Biodistribution and Tumour Accumulation of [89Zr]-Df-CriPec® Docetaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cristal Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical phase I, open-label PET study with [89Zr]-Df-CriPec® docetaxel in patients with&#xD;
      solid tumours to assess biodistribution and tumour accumulation of [89Zr]-Df-CriPec®&#xD;
      docetaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After patient inclusion an fludeoxyglucose-18 ([18F]-FDG) PET scan will be performed to&#xD;
      delineate viable tumour lesions. On day 1, patients will receive a low dose of&#xD;
      [89Zr]-Df-CriPec® docetaxel (corresponding to approximately 0.1-1 mg docetaxel) followed by&#xD;
      maximally 3 [89Zr] PET scans (timing of PET scan can be adapted depending on results&#xD;
      obtained, within timeframe of 2 h - 9 days after administration) to evaluate biodistribution&#xD;
      and tumour uptake. Two weeks later, the patients will receive unlabelled CriPec® docetaxel up&#xD;
      to the Recommended Phase II Dose (RP2D) given every 3 weeks (Q3W) that will be determined in&#xD;
      the phase I NAPOLY trial (CT-CL01), immediately followed by a second low dose of&#xD;
      [89Zr]-Df-CriPec® docetaxel and maximally 3 [89Zr]PET scans (timing of PET scan can be&#xD;
      adapted depending on results obtained, within timeframe of 2 hrs - 9 days after&#xD;
      administration) to evaluate biodistribution and tumour uptake with therapeutic dosage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">May 8, 2020</completion_date>
  <primary_completion_date type="Actual">March 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase I, open-label, single centre immune-PET study with [89Zr]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of [89Zr]-Df-CriPec® docetaxel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection (visual) of [89Zr]-Df-CriPec® docetaxel in tumour lesions (the short axis diameter of a visually assessable and quantifiable lesion must be ≥ 2 cm)</measure>
    <time_frame>14 days</time_frame>
    <description>Visual detection (absent/present) of tumor uptake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection (quantitative) of [89Zr]-Df-CriPec® docetaxel in tumour lesions (the short axis diameter of a visually assessable and quantifiable lesion must be ≥ 2 cm)</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by SUVpeak values of visual positive lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosimetry of [89Zr]-Df-CriPec® docetaxel</measure>
    <time_frame>14 days</time_frame>
    <description>Based on 89Zr PK activity concentration (Bq/ml) and biodistribution [89Zr]-Df-CriPec® docetaxel scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal time point for PET imaging after [89Zr]-Df-CriPec® docetaxel administration</measure>
    <time_frame>14 days</time_frame>
    <description>As assesed by a multidisciplinairy team</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity between [89Zr]-Df-CriPec® docetaxel and total docetaxel</measure>
    <time_frame>14 days</time_frame>
    <description>Assessment of 89Zr PK (Bq/ml) and total docetaxel (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biodistribution of low dose dose [89Zr]-Df-CriPec® docetaxel before and after administration of therapeutic dose of CriPec® docetaxel (quantified with %ID [89Zr] CriPec® docetaxel)</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by defining volumes of interest (VOI) of various organs on PET scan and calculating %ID/kg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Patients [89Zr]-Df-CriPec® docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 of the Run-in a low dose of [89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed &lt; 2 h by a second low dose of [89Zr]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of [89Zr]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cripec Docetaxel</intervention_name>
    <description>89 Zirconium Cripec Docetaxel PET</description>
    <arm_group_label>Patients [89Zr]-Df-CriPec® docetaxel</arm_group_label>
    <other_name>89 Zirconium Cripec Docetaxel PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        To be eligible to participate in this study, candidates must meet the following eligibility&#xD;
        criteria:&#xD;
&#xD;
        1. Age ≥ 18 years 2 A pathologically confirmed diagnosis of advanced, recurrent and&#xD;
        progressive cancer that is refractory to standard therapy or for which no standard therapy&#xD;
        exist and where treatment with a taxane is an appropriate treatment option 3. Measurable or&#xD;
        evaluable disease according to RECIST criteria v.1.1 Patient must have at least one&#xD;
        measurable lesion with a short axis diameter of ≥ 2 cm.&#xD;
&#xD;
        4. Performance status (WHO scale/ ECOG) ≤ 1 (appendix 2) 5. Estimated life expectancy of at&#xD;
        least 12 weeks 6. Toxicities incurred as a result of previous anti-cancer therapy&#xD;
        (radiation therapy, chemotherapy, or surgery) must be resolved to ≤ grade 2 (as defined by&#xD;
        CTCAE version 4.0) 7. ANC ≥ 1.5 x10E9/L; platelets ≥ 100 x 10E9/L; Haemoglobin ≥ 6.0 mmol/L&#xD;
        (≥ 9.6 g/dL) 8. Creatinine ≤ 1.5 x upper limit of normal (ULN); or creatinine clearance ≥&#xD;
        60 mL/ min (Cockcroft-Gault) 9 Serum bilirubin ≤1.5 x ULN, alkaline phosphatase, ASAT and&#xD;
        ALAT ≤ 2.5 x ULN, unless related to liver metastases, in which case ≤ 5x ULN is allowed 10&#xD;
        Written informed consent according to local guidelines&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Candidates will be excluded from study entry if any of the following exclusion criteria are&#xD;
        met:&#xD;
&#xD;
          1. Less than 4 weeks since the last treatment with other anti-cancer therapies, (i.e.&#xD;
             endocrine therapy, immunotherapy, radiotherapy, chemotherapy, etc.), less than 8 weeks&#xD;
             for cranial radiotherapy, and less than 6 weeks for nitrosoureas and mitomycin C prior&#xD;
             to first study treatment.&#xD;
&#xD;
          2. A history of skin toxicity as a result of prior treatment with taxanes&#xD;
&#xD;
          3. If excessive sequestering of [ 89 Zr] CriPec®docetaxel in healthy liver is observed in&#xD;
             the first 3 patients, patients with only liver lesion will not be eligible.&#xD;
&#xD;
          4. Current or recent (within 28 days of first study treatment) treatment with another&#xD;
             investigational drug or participation in another investigational study.&#xD;
&#xD;
          5. Active or symptomatic brain metastases. Patients must be on a stable or deceasing dose&#xD;
             of corticosteroids and/ or have no requirement for anticonvulsants for 5 days prior to&#xD;
             Cycle 1 Day 1.&#xD;
&#xD;
          6. Current malignancies at other sites, with exception of adequately treated&#xD;
             cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          7. Major surgical procedure (including open biopsy, excluding central line IV and port-a-&#xD;
             cath) within 27 days prior to the first study treatment, or anticipation of the need&#xD;
             for major surgery during the course of the study treatment&#xD;
&#xD;
          8. Uncontrolled hypertension (systolic &gt;150 mmHg and/ or diastolic &gt; 100 mmHg)&#xD;
&#xD;
          9. Grade ≥ 2 motor or sensory neuropathy symptoms (as defined by CTCAE version 4.03)&#xD;
&#xD;
         10. Known hypersensitivity to any of the study drugs or excipients or taxanes&#xD;
&#xD;
         11. Any active skin condition associated with impaired skin integrity exposing the patient&#xD;
             at risk to develop skin toxicity 12 Clinically significant (i.e. active)&#xD;
             cardiovascular disease defined as:&#xD;
&#xD;
               -  Stroke within ≤ 6 months prior to first study treatment;&#xD;
&#xD;
               -  Transient Ischemic Attack (TIA) within ≤ 6 months prior to first study treatment&#xD;
                  ;&#xD;
&#xD;
               -  Myocardial infarction within ≤ 6 months prior to first study treatment;&#xD;
&#xD;
               -  Unstable angina;&#xD;
&#xD;
               -  New Yotk Heart Association (NYHA) Grade II or greater Congestive Heart Failure&#xD;
                  (CHF);&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication;&#xD;
&#xD;
               -  Clinically relevant pathologic findings in electrocardiogram (ECG)&#xD;
&#xD;
               -  Left ventricle Ejection Fraction (LVEF) by MUGA or ECHO &lt; 50% 13 Patients who are&#xD;
                  pregnant or breastfeeding 14 Absence of effective means of contraception as of&#xD;
                  Run-in Day 1 in female patients of childbearing potential (defined as &lt; 2 years&#xD;
                  after last menstruation and not surgically sterile) ore in male patients who are&#xD;
                  not surgically sterile and who have female partners if childbearing potential 15&#xD;
                  Evidence of any other medical conditions (such as psychiatric illness, infectious&#xD;
                  diseases, drug or alcohol abuse, physical examination or laboratory finding) that&#xD;
                  may interfere with the planned treatment, affect patient compliance or place the&#xD;
                  patient at high risk from treatment- related complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord- Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>C. Menke- van der Houven van Oordt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Nanoparticles</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Quantification</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

